CLYM Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
16.9M
+10.0%
15.4M
+1.0%
15.2M
-21.2%
19.3M
+29.6%
14.9M
R&D
11.0M
+13.7%
9.7M
+3.6%
9.4M
-31.8%
13.7M
+51.4%
9.1M
SG&A
5.8M
+3.6%
5.6M
-3.3%
5.8M
+5.0%
5.6M
-4.5%
5.8M
Operating Income
-16893000
-10.0%
-15359000
-1.0%
-15211000
+21.2%
-19296000
-29.6%
-14892000
EBITDA
-16698000
-9.0%
-15326000
-1.0%
-15173000
+21.2%
-19266000
-29.6%
-14863000
Net Income
-15034000
-11.4%
-13498000
+1.6%
-13722000
+21.7%
-17516000
-37.5%
-12737000
EPS (Basic)
$-0.18
+0.0%
$-0.18
+10.0%
$-0.20
+23.1%
$-0.26
-36.8%
$-0.19
EPS (Diluted)
$-0.18
+0.0%
$-0.18
+10.0%
$-0.20
+23.1%
$-0.26
-36.8%
$-0.19
Shares (Diluted)
80.0M
+5.1%
76.2M
+11.7%
68.2M
+0.0%
68.2M
+0.3%
68.0M
Climb Bio (CLYM) — Financials